Surgical and post-operative data for overall population (n=365) and according to chemotherapy response score (CRS)
| Overall (n=365) | CRS 1–2 (n=277) | CRS 3 (n=88) | P value | |
| PCI, n (%) | ||||
| ≤10 >10 Median (range) Missing | 205 (56.5) 158 (43.5) 9 (0–39) 2 (-) | 132 (47.8) 144 (52.2) 11 (0–39) 1 (-) | 73 (83.9) 14 (16.1) 4 (0–19) 1 (-) | <0.001 |
| NACT, n (%) | ||||
| 3–4 cycles 6 cycles | 219 (60.0) 146 (40.0) | 174 (62.8) 103 (37.2) | 45 (51.1) 43 (48.9) | 0.051 |
| CC-score | ||||
| CC-0 CC-1 | 318 (87.1) 47 (12.9) | 231 (83.4) 46 (16.6) | 87 (98.9) 1 (1.1) | <0.001 |
| Aletti score, n (%) | ||||
| <8 ≥8 | 213 (58.4) 152 (41.6) | 139 (50.2) 138 (49.8) | 74 (84.1) 14 (15.9) | <0.001 |
| Post-operative complications*, grade III/IV, n (%) | ||||
| No Yes | 294 (80.5) 71 (19.5) | 218 (78.7) 59 (21.3) | 76 (86.4) 12 (13.6) | 0.114 |
| Bevacizumab maintenance, n (%) | ||||
| No Yes | 290 (79.5) 75 (20.5) | 213 (76.9) 64 (23.1) | 77 (87.5) 11 (12.5) | 0.032 |
| Platinum resistance†, n (%) | ||||
| *No Yes Missing | 272 (77.5) 79 (22.5) 14 (-) | 194 (73.5) 70 (26.5) 13 (-) | 78 (89.7) 9 (10.3) 1 (-) | 0.002 |
*Platinum resistance defined as early relapse within 6 months after last cycle of carboplatin.
†Clavien-Dindo classification.
CC, complete cytoreduction; CRS, chemotherapy response score; NACT, neoadjuvant chemotherapy; PCI, peritoneal cancer index.